Expanding our COVID-19 antivirals platform

We’re excited to share that Color’s COVID-19 antivirals test-to-treat program now supports the prescription of molnupiravir (Lagevrio). Throughout the COVID-19 pandemic, Color has been committed to ensuring that individuals who need access to life-saving COVID-19 testing, vaccinations, and treatments are able to get access, no matter where or when they need it. Over the past several months, Color has supported our test-to-treat program, which provides both video- and phone-based clinician consultations to ensure individuals who test positive for COVID-19 have access to life-saving antiviral treatments that can decrease the risk of hospitalization. Now, Color supports molnupiravir as an antiviral treatment option for all of our test-to-treat antiviral programs.

For patients where Paxlovid is contraindicated and other recommended treatments like remdesivir (Veklury) or bebtelovimab are not available, clinicians will be able to prescribe molnupiravir for nonpregnant individuals. This access is incredibly important, especially for those most in-need of antiviral intervention. Older patients (85+) who already experience difficulty in accessing medical care, have a 330 times higher mortality rate than those within the 18 to 29 years age group. Combined with the fact that less than a third of rural Americans have received a COVID-19 booster vaccine, programs like these are a tool for organizations to minimize hospitalization rates and decrease the risk of death in their populations. 

On Color’s platform, after testing positive for COVID-19, patients over 18 years old complete a short intake process, meet with a clinician on a telehealth consult, and, if eligible, receive a prescription for the COVID-19 antiviral that best suits their needs. Through the platform, Color also helps individuals find pharmacies that carry their selected COVID-19 antiviral or schedule an at-home prescription delivery. 

In addition to our free telehealth consultations, Color now provides phone consultations; a simpler, lower-tech option for individuals who may not be able to access telehealth video calls. In fact, our research shows that between mid-September and mid-October of 2022, 75% of our COVID-19 test-to-treat antiviral program participants chose a phone call over a video call. Additionally, of those who chose a phone consult, 28% were 65 years of age or older and 21% were from communities who have a high Social Vulnerability Index score. 

By expanding the options of COVID-19 antiviral treatments, our program inherently broadens its reach to serve more populations. In doing so, Color continues to quell the effects of the COVID-19 pandemic on communities, keeping us safer and healthier as we head into the holiday season. 

Contact us if you’re interested in learning more about how Color can help your organization.